Moderna (MRNA) could be the COVID-19 winner
What’s up with Moderna?
Moderna (MRNA) opened at $48.71, which means the stock is up 4.37 from yesterday’s closing price of 45.99. Today, the company has a high of $50.45 and a low of $46.29. The company has a market cap of $15.77 billion with a 52-week high of $56.38 and a 52-week low of $11.54.
What about the future for Moderna
The high forecast for Moderna is 83.00 while the low is 32.00. Stock forecasts are based on human experience: Human traders based on their experience in terms of stock price patterns, volume changes, and market news/rumors regarding a particular stock. Moderna has a strong forecast. A strong forecast is a result of strong earning reports as investors are willing to pay a higher share price today because of growth expectations in the future.. Based on this information MRNA seems to be a safe buy.
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.